Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Cannara Biotech (V.LOVE) Reports Fourth Quarter and 2023 Fiscal Year Results (click to learn more) Pulsar’s New Presentation Includes New Images for the Passive Seismic Survey (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neogenomics Inc NEO

Healthcare
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: Clinical Services, and Advanced Diagnostics. The Clinical Services segment provides various clinical-testing services related to oncology diagnostics, community-based oncology and pathology sales, patient engagement, and clinical decision support. The Clinical Services segment also offers Trapelo, a decision-making informatics tool, to help health care professionals navigate the rapidly evolving field of precision medicine. The Advanced Diagnostics segment includes pharma services, informatics, research and development, and minimal residual disease, liquid biopsy and therapy selection business development. Additional offerings within the Advanced Diagnostics portfolio include Informatics, which involves the licensing of de-identified data to pharmaceutical and biotech customers in the form of either retrospective records or prospective deliveries of data.


NDAQ:NEO - Post by User

Neogenomics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
  • zeropointenergyX
Comment by zeropointenergyon Mar 19, 2021 2:45am
170 Views
Post# 32835819

RE:spending US$4.5bn to expand capacity at plants in the Chines

RE:spending US$4.5bn to expand capacity at plants in the Chines

China EV startup Nio's shipments are beginning to take off    Nice read!

<< Previous
 Bullboard Posts
Next >>